Aristotle University Of Thessaloniki (AUTH)
Echocardiographic indices and biomarkers in patients with elevated pulmonary pressures due to left heart diseases
Abstract
dc:descriptionPulmonary hypertension secondary to left heart diseases (PH-LHD) is the most common form of pulmonary hypertension, representing about 80% of pulmonary hypertension cases. It is associated with an increased pulmonary venous pressure and is the second of a total of five groups recognised in the classification of PH. It is not a diagnosis by itself but it is a clinical entity due to various left ventricular diseases, each one requiring different treatment modalities and presenting with a divergent prognosis, all of them converging, however, in increased morbidity and mortality.The diagnosis of group 2 PH relies on a clinical probability assessment in which echocardiography plays a major role, eventually followed by the invasive measurements of a mean pulmonary artery pressure (mPAP) ≥ 25 mmHg and a wedged PAP (PCWP) > 15 mmHg. This combination of mPAP and PCWP defines “post-capillary PH”.The cause of PH- LHD is upstream transmission of increased pulmonary venous pressure occurring in the setting mostly on heart failure (HF) with either decreased left ventricular (LV) ejection fraction (EF) (HFrEF) or preserved LVEF (HFpEF) or mitral or aortic valvular diseases. PH-LHD is a cause of decreased exercise capacity and systemic congestion, and is associated with a poor prognosis. The abnormal pulmonary hemodynamic occurs since early stages of HF and may be unmasked in patients already receiving optimal HF therapy, representing a target of specific therapeutic interventions.The development of pulmonary hypertension in left heart failure is not solely caused by a passive increase in pulmonary vascular pressure, but is commonly aggravated by a concomitant rise in pulmonary vascular resistance (PVR) that is attributable to increased pulmonary vascular tone and extensive lung vascular remodeling. Both of these phenomena have been proposed to be triggered by lung endothelial dysfunction and altered RV- arterial coupling. Post-capillary PH is associated with a decreased survival in proportion to increased PAP and decreased right ventricular (RV) ejection fraction.The diagnosis of PVH is still challenging. Echocardiography offers estimates of the components of the PVR equation as mPAP can be recalculated from the maximum velocity of tricuspid regurgitation. Imaging by echocardiography also offer measurements of cardiac chambers and dimensions, and are thus essential to the diagnosis of HF with or without preserved EF and valvulopathies, and for the evaluation of RV function, where the latter is an important component of the diagnosis of PH-LHD. Because the diagnosis of postcapillary PH requires the integration of measurements of the pulmonary circulation combined with imaging of RV and LV structure and function, the idea has come to elaborate echocardiographic prediction scores. Biomarkers are not always sensitive enough to differentiate between systolic and diastolic HF, but they can provide important and quite often definitive information to ascertain the diagnosis and prognosis of HF, specially in a state with severe PH.The purpose of this study wasto identify novel echocardiographic parameters and biomarkers for the diagnosis and prognosis of pulmonary venous hypertension, in order to systematically elucidate the role of these parameters in assessing the severity of PVH and their predictive value on survival/mortality.We analyzed sixty-four (33 males, 31 females, mean age 74 years) consecutive patients with PH-LHD, and 20 (11 males, 9 females, mean age 42 years) healthy volunteers were recruited and assessed in our echo-lab. Left heart diseases (coronary artery disease, cardiomyopathy, valvulopathy), right ventricle function, pulmonary circulation were evaluated by 2D and Doppler (CW, PW, TDI) and the following parameters were recorded: LV EF, FAC RV, TAPSE, LA and RA area, LA and RA volume, LAVi, PR end-dias, Augmented pressure (AP), pulmonary pressure reflection (tPV-PP), AP/RVSP x 100, RVSP, PaccT, RAP, MV E/A, MV E/e’, TV E/A, TV E/e’, free RV S, PCWP, LV MPI, RV MPI, free RV IVRT, Lei diastole, Lei systole, S/L ED (SI), LAI RV, PVR (using the Abbas formula), LVEDD, LVESD, TAPSE/RVSP, ePLAR. Moreover, we investigated the following parameters: IVA, sphericity index (S/L ED- SI), LAI RV, TAPSE/RVSP, ePLAR, RV-IVRT, pulmonary reflection variables, augmented pressure, including TAPSE, S’, RVFAC, MPI, LV systolic and diastolic parameters, and analyzed the value of these indices in predicting RV dysfunction, as a strong and independent predictor of survival in patients with heart failure. Furthermore, impaired RV–PA coupling (presenting by TAPSE/RVSP ratio) appears to be of particular importance to outcomes specially in HFpEF. Three biomarkers were also measured: NT-proBNP, hs-troponine, Galectine 3. And a subgroup of 35 patients was completed with right catheterisation. The mean follow-up period was 17.8 months. The primary endpoint was 12-month mortality.Results showed: All the aforementioned echocardiographic indices (except from AP/RVSPx100, RV MPI, S/L ED) differed significantly between PH-LHD patients and controls (p<0.05). All biomarkers differed significantly between the two groups (p<0.05). Mortality rate was 39.1% in the patient’s group. LVEF, Galectine 3, NYHA class, presence of diabetes and valvulopathy differed significantly between survivors and nonsurvivors in the PH-LHD group. However multivariable regression analysis, identified galectine-3, LV EF and NYHA IV, as the strongest predictors for all cause mortality. Further analysis revealed that patients who died from severe PH and/or worsening HF (n=25) had particularly high levels of galectin-3 > 30 ng/dl. All the analysis suggests that NYHA IV, galectine >30ng/dl and LVEF < 40% might identify patients at high risk for all-cause mortality. And in the multivariate analysis only advanced NYHA class IV significantly predicted mortality (95% CI: 0.016-0.253, p<0.001).The present study shows the prognostic importance of NYHA functional class on outcomes in patients with PVH and that multiple echocardiographic parameters and biomarkers are influenced in PH-LHD. Furthermore, it clearly delineates that in addition to advanced age and higher pulmonary pressures, distinct hemodynamic parameters reflecting both LV filling impairment and pulmonary vascular disease underliethe cardinal symptom of HF and PH.Group 2 PH is commonly identified in patients with chronic stable HF and carries a significantly increased mortality risk. The development of mixed PH with structural and/or functional pulmonary vascular disease is related to other markers of increased HF severity and chronicity, and carries incrementally greater risk of death. PH-associated left-sided heart failure is a risk factor for poorer outcomes and an indication for advanced heart failure therapies including medical, LVADs, or surgical or catheter-based valve repair or replacement which, despite an increased risk for intervention, are frequently associated with excellent outcomes and resolution of the PH. Thus, future treatment efforts should target both the left ventricle and the pulmonary vasculature to alleviate symptoms and improve outcomes.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2019
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Kristo, Diana
- Χρήστου, Ντιάνα
Subjects
dc:subject × 6Rights
- Language dc:language
- eng
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/45238